Clinical trials: Oral Manifestations
Seizures
A Study of the Pharmacokinetics, Safety and Tolerability of Topiramate in Infants (Age 1-24 Months) With Refractory Partial-onset Seizures
The purpose of this study is to evaluate the pharmacokinetics safety and tolerability of topiramate in infants aged 1-24 months with refractory partial-onset seizures.
- Trial name
- NCT00233012
- Testing
- Topiramate
- Volunteers
- 16 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Immune Thrombocytopenia
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
This is a multinational, open label, single arm study that will evaluate the impact of early multi-immune modulation with rilzabrutinib in adult ITP patients who failed first-line treatment.
- Trial name
- LUNA 4 (NCT07007962)
- Testing
- rilzabrutinib
- Where
- 36 sites in United States, Austria and 7 more
- Volunteers
- 60 people
- Sponsor
- Sanofi
Paralysis, Paralysis; Eye
Evaluate the Usability of the Neuro-trigger Artificial Eye Blinking Stimulation Device in Patients With Paralysis of the Facial Nerve.
This is a single-center, open-label clinical study. Up to 11 subjects will be enrolled to use the Neuro-trigger device for blinking stimulation for a duration of 14 days.
- Conditions
- Paralysis, Paralysis; Eye, Paralysis; Bell
- Trial name
- paralysis (NCT06069128)
- Testing
- Neurotrigger Basic. eye blinking stimulator
- Where
- Israel
- Volunteers
- 11 people
- Sponsor
- Neurotrigger Ltd
Pain; Bone Neoplasms; Neoplasm Metastasis
A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease
This study will assess the efficacy and safety of ibandronate (Bondronat), administered intravenously (IV) or orally (PO), in participants with malignant bone disease and moderate to severe pain.
- Trial name
- NCT02561039
- Testing
- Ibandronate
- Where
- 9 sites in Bulgaria
- Volunteers
- 97 people
- Sponsor
- Hoffmann-La Roche
Healthy
A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers
The main purpose of this study is to determine if oxycodone and naltrexone combination capsules (ALO-02) have the potential to be abused.
- Trial name
- NCT01746901
- Testing
- intact ALO-02 60 mg/7.2 mg, crushed ALO-02 60 mg/7.2 mg, crushed oxycodone IR 60 mg
- Where
- Canada
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Pfizer
Overactive Bladder
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of DA-8010 in Healthy Subjects
This study is a Phase I, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics After Single and Multiple Oral Administration of DA-8010 in Healthy Subjects.
- Trial name
- NCT02821312
- Testing
- DA-8010
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Healthy
Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066
The study is carried out in order to determine the relationship between AZD2066 exposure and mGluR5 receptor occupancy in the brain and to demonstrate that AZD2066 can displace [11C]AZ12713580 from mGluR5 binding-sites in the…
- Trial name
- PET (NCT00686504)
- Testing
- AZD2066, radioligand [11C] AZ12713580
- Where
- Sweden
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pain, Postoperative Pain
A Comparative Study of JNS013 in Participants With Post-Tooth-Extraction Pain
The purpose of this study is to evaluate the efficacy and safety of JNS013 with single oral dose administration in participants with pain after tooth-extraction of mandibular impacted wisdom tooth.
- Trial name
- NCT00737048
- Testing
- Tramadol Hydrochloride, Acetaminophen, Tramadol plus Acetaminophen
- Where
- 11 sites in Japan
- Volunteers
- 328 people
- Sponsor
- Janssen Pharmaceutical K.K.
Pruritus
Bioequivalence Study of Nalfurafine Hydrochloride Orally Disintegrating Tablets on Fasting and Fed in Humans
The test formulation of Nalfurafine Hydrochloride Orally Disintegrating Tablets (2.5 μg) is bioequivalent to the reference formulation (Remitch®) in healthy Chinese subjects under fed conditions.
- Trial name
- NCT07478133
- Testing
- Nalfurafine Hydrochloride Orally Disintegrating Tablets, Remitch®
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Partial Seizure Disorder, Epilepsy
Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures
The purpose of this study is to evaluate the tolerability, safety and efficacy of topiramate in infants with refractory partial onset seizures (POS).
- Conditions
- Partial Seizure Disorder, Epilepsy, Seizures
- Trial name
- NCT00113815
- Testing
- topiramate
- Where
- 94 sites in United States, Argentina and 21 more
- Volunteers
- 118 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Dyskinesias, Drug-induced
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
This study will assess the safety, tolerability and efficacy of AQW051 in treating moderate to severe L-dopa induced dyskinesias (movement disorders) in patients with Parkinson's disease.
- Trial name
- NCT01474421
- Testing
- AQW051
- Where
- 24 sites in United States, France and 2 more
- Volunteers
- 71 people
- Sponsor
- Novartis Pharmaceuticals
Prader-Willi Syndrome
A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome
This is a Phase 3 open-label extension (OLE) study in patients diagnosed with Prader-Willi Syndrome (PWS) who completed the Maintenance Period of the randomized, placebo-controlled Phase 2/3 study SCOUT-015.
- Trial name
- NCT05387798
- Testing
- RAD011
- Sponsor
- Radius Pharmaceuticals, Inc.
Migraine
A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.
- Trial name
- NCT04804033
- Testing
- BHV-3500 (zavegepant)
- Where
- 116 sites in United States
- Volunteers
- 1,753 people
- Sponsor
- Pfizer
Crohn's Disease
Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation
The purpose of this study is to evaluate the effects and safety of OPS-2071 (150, 300, or 600 mg twice a day [BID]) versus placebo, as add-on therapy in participants with Crohn's disease who show symptoms of active inflammation…
- Trial name
- NCT03850509
- Testing
- OPS-2071
- Where
- 31 sites in United States, Poland
- Volunteers
- 3 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Pain, Postoperative
Study of Oral Morphine Sulfate Administration in Pediatric Subjects
This is a multicenter, open-label study to evaluate the safety and PK of oral morphine sulfate in pediatric subjects with post-operative pain.
- Trial name
- NCT03429400
- Testing
- Morphine Sulfate
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- West-Ward Pharmaceutical
Urinary Incontinence
DBPC Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine in Subjects With Urinary Incontinence
This study will explore the safety, tolerability and efficacy of litoxetine in men and women who suffer from urinary incontinence
- Trial name
- NCT03397771
- Testing
- Litoxetine
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Ixaltis SA
Pain, Postoperative, Postoperative Pain
Pharmacokinetics and Safety Study of Tapentadol for Postsurgical Pain in Children and Adolescents
The purpose of this study is to evaluate the pharmacokinetic (PK) profile; and safety and tolerability of a single dose of tapentadol oral solution (OS) 1 mg/kg in children and adolescents aged from 6 to less than 18 years with…
- Trial name
- NCT01134536
- Testing
- Tapentadol (OS) Oral Solution
- Where
- 17 sites in United States, Canada and 2 more
- Volunteers
- 45 people
- Sponsor
- Janssen Research & Development, LLC
Acute Ischaemic Middle Cerebral Artery Stroke
A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke
The aim of this study was to confirm the efficacy of piracetam after 12 weeks of treatment on the aphasic status of subjects suffering from aphasia after acute ischemic middle cerebral artery stroke and having received their…
- Trial name
- NCT01883011
- Testing
- Piracetam
- Where
- 44 sites in Argentina, Austria and 13 more
- Volunteers
- 571 people
- Sponsor
- UCB S.A. - Pharma Sector
Overactive Bladder
Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms
This study will test the effectiveness and safety of two doses of solabegron against placebo in reducing the symptoms of overactive bladder.
- Trial name
- NCT00343486
- Testing
- Solabegron
- Where
- 66 sites in Argentina, Australia and 12 more
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Bell's Palsy, Ramsay Hunt Syndrome
Safety and Effectiveness of the BlinkER System in Participants With Facial Nerve Palsy
Prospective, single-arm, multicenter, single-masked, pivotal study to Evaluate the Safety and Effectiveness of the Blinker system in Participants with Facial Nerve Palsy.
- Conditions
- Bell's Palsy, Ramsay Hunt Syndrome, Lyme Disease, Facial Palsy
- Trial name
- Paralysis (NCT06542289)
- Testing
- BlinkER device.
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Neurotrigger Ltd